The article reviews top Wall Street forecasters' predictions for 2026, highlighting their accurate calls on the S&P 500's 17% rally in 2025, the market bottom after tariff-induced declines, and a significant surge in gold prices, along with their investment recommendations.
Eli Lilly raised its full-year profit and sales forecasts driven by strong demand for its weight-loss drug Zepbound, although its new oral drug orforglipron underperformed expectations, leading to a stock decline. The company is competing with Novo Nordisk in the lucrative GLP-1 agonist market, with Lilly's market share increasing and sales surpassing analyst estimates, prompting optimistic revenue and profit outlooks for 2025.